Diseases

Imbruvica receives positive opinion from CHMP

July 3, 2019 Pharma News HQ 0

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended expanding the existing marketing authorisation (MA) for Janssen’s Imbruvica (ibrutinib) to include chronic lymphocytic leukaemia (CLL) and Waldenström’s macroglobulinemia (WM). The drug […]